Is HRT Safe? What the Evidence Says in 2026

This is the question that has kept millions of women from treatment. Let's answer it honestly, based on the best evidence as of 2026.

The bottom line, up front

For most women younger than 60 or within 10 years of menopause onset who have no contraindications, major menopause guidance says the benefits of HRT for bothersome symptoms generally outweigh the risks. That is the position of The Menopause Society, the Endocrine Society and the International Menopause Society. The FDA began approving product-specific boxed-warning updates in February 2026, but that regulatory action does not by itself decide whether HRT is appropriate for an individual.

Where the fear came from

In 2002, the Women's Health Initiative (WHI) published results that appeared to show increased risks of breast cancer and heart disease. But the study had critical limitations: the average participant was 63 (not the typical HRT user), many had pre-existing cardiovascular risks, and the hormones used (conjugated equine estrogen + synthetic progestin) aren't what most women are prescribed today.

What 20+ years of follow-up research shows

Estrogen-only HRT: No increased breast cancer risk - possibly protective. No cardiovascular risk when started within the timing window.

Micronized progesterone (Prometrium): Significantly better safety profile than the synthetic progestin used in the WHI. The French E3N study found no increased breast cancer risk over 8 years.

Transdermal estrogen (patches, gels): Does not raise clotting factors the way oral estrogen does. A prior clot, stroke or heart attack is still a label contraindication for any systemic route.

Timing matters: Starting HRT before 60 or within 10 years of menopause may actually be cardioprotective. Starting later carries more risk.

Risks in context

Even with the least favorable HRT formulation (oral estrogen + synthetic progestin), the absolute risk increase was ~8 additional breast cancer cases per 10,000 women per year - comparable to the risk from obesity, 2+ daily alcoholic drinks, or a sedentary lifestyle.

Modern HRT regimens (bioidentical estradiol patches + micronized progesterone) carry a meaningfully lower risk profile than what was studied in the WHI.

The FDA's landmark decision

In November 2025, the FDA asked manufacturers to remove the cardiovascular disease, breast cancer and probable dementia statements from the boxed warning, and since February 2026 it has been approving updated labels product by product; products without an approved update may still carry the older warning. HHS described the old warnings as "misleading", and critics had long argued that they failed to distinguish between different types, delivery methods, patient populations, and timing, and scared some women away from individually appropriate treatment.

It was a narrowing rather than a clean sweep. For updated systemic estrogen-alone labels, the endometrial cancer boxed warning remains. Anyone with a uterus who uses systemic estrogen generally also needs a plan to protect the uterine lining, while low-dose vaginal estrogen generally does not require an added progestogen. The FDA did not change the contraindications.

Who should be cautious

HRT should be avoided or used carefully in women with current or past breast cancer of any receptor status, a history of blood clots, pulmonary embolism, stroke or heart attack, active liver disease, or unexplained vaginal bleeding. Note that the label excludes a past event, not only an active one. Even in these cases, vaginal estrogen (minimal systemic absorption) may be appropriate.

The right approach

Not "HRT is dangerous" or "HRT is safe for everyone." The right question is: "What are MY individual risks and benefits?" A good provider will assess your personal history, family history, risk factors, and symptoms to make an individualized recommendation.